Rhythm Pharmaceuticals (RYTM) Tops Q4 EPS by 9c
Tweet
Share
E-mail
Get Alerts RYTM Hot Sheet
Join SI Premium – FREE
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q4 EPS of ($0.73), $0.09 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $57.3 million versus the consensus estimate of $55.24 million.
For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- FGI Industries Ltd (FGI) Tops Q2 EPS by 59c
- Alto Neuroscience, Inc. (ANRO) Tops Q2 EPS by 10c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
